Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 9:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 136 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Iressa (ZD1839) Clear all
Completed Phase 2 Interventional

Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors

NCT00025675
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
gefitinib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Bethesda, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 6, 2026, 9:50 PM EDT
Completed Phase 1 Interventional

Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma

NCT00027625
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
gefitinib, temozolomide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Bethesda, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 6, 2026, 9:50 PM EDT
Terminated Phase 2 Interventional Results available

Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer

NCT00479089
View directory record Official record
Conditions
Bladder Cancer
Interventions
Docetaxel, ZD1839, Dexamethasone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Oct 6, 2026, 9:50 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer

NCT00317772
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Cancer
Interventions
Topotecan, Gefitinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Oct 6, 2026, 9:50 PM EDT
Completed Phase 1 Interventional

Calcitriol and Gefitinib With or Without Dexamethasone in Treating Patients With Advanced Solid Tumors

NCT00084708
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
calcitriol, dexamethasone, gefitinib
Dietary Supplement · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 6, 2026, 9:50 PM EDT
Completed Phase 2 Interventional

Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer

NCT00049062
View directory record Official record
Conditions
Breast Cancer
Interventions
anastrozole, gefitinib
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Oct 6, 2026, 9:50 PM EDT
Completed Phase 1 Interventional

Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer

NCT01967095
View directory record Official record
Conditions
EGFR-Mutant Lung Cancer
Interventions
erlotinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Oct 6, 2026, 9:50 PM EDT
Completed Phase 2 Interventional

Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim

NCT00280787
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Paclitaxel, Carboplatin, CPT-11, Pegfilgrastim, Conformal radiotherapy
Drug · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Oct 6, 2026, 9:50 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

NCT03122717
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Gefitinib, Osimertinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 6, 2026, 9:50 PM EDT
Completed Phase 1 Interventional

Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck

NCT00185835
View directory record Official record
Conditions
Head and Neck Cancer, Carcinoma, Squamous Cell
Interventions
ZD-1839, Cisplatin
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2010 · Synced Oct 6, 2026, 9:50 PM EDT
Completed Phase 2 Interventional Results available

Iressa Study in Patients With Salivary Gland Cancer

NCT00509002
View directory record Official record
Conditions
Salivary Gland Cancer
Interventions
Gefitinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 6, 2026, 9:50 PM EDT
Completed Phase 2 Interventional

Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer

NCT00100945
View directory record Official record
Conditions
Esophageal Cancer
Interventions
gefitinib
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
119
States / cities
Mobile, Alabama • Jacksonville, Florida • Aurora, Illinois + 77 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Oct 6, 2026, 9:50 PM EDT
Completed Phase 2 Interventional

Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)

NCT00071994
View directory record Official record
Conditions
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions
gefitinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Oct 6, 2026, 9:50 PM EDT
Terminated Phase 2 Interventional

Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients

NCT00206492
View directory record Official record
Conditions
Breast Cancer
Interventions
Iressa, Tamoxifen
Drug
Lead sponsor
Baylor Breast Care Center
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 6, 2026, 9:50 PM EDT
Completed Not applicable Interventional Results available

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

NCT02551718
View directory record Official record
Conditions
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Acute Leukemia of Ambiguous Lineage
Interventions
Chemosensitivity Assay, Cytology Specimen Collection Procedure, Gene Expression Analysis, Genetic Variation Analysis, In Vitro Sensitivity-Directed Chemotherapy
Other · Genetic · Drug
Lead sponsor
University of Washington
Other
Eligibility
3 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 6, 2026, 9:50 PM EDT
Terminated No phase listed Observational Results available

Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma in Non Small Cell Lung Cancer

NCT02762877
View directory record Official record
Conditions
Non Small Cell Lung Carcinoma
Interventions
Not listed
Lead sponsor
Genomic Health®, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
Torrance, California • Macon, Georgia • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 6, 2026, 9:50 PM EDT
Recruiting Phase 2 Interventional

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

NCT07477457
View directory record Official record
Conditions
Osteosarcoma, Metastasis
Interventions
Methotrexate, Doxorubicin, Cisplatin, Gefitinib, Trametinib, Disulfiram, Sunitinib, Ifosfamide, Biopsy
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
6 Years to 49 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 6, 2026, 9:50 PM EDT
Completed Phase 2 Interventional

ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck

NCT00015964
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
ZD1839
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
11
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 6, 2026, 9:50 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer

NCT00231465
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
docetaxel (Taxotere®), ZD1839
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
70 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 6, 2026, 9:50 PM EDT
Completed Phase 2 Interventional

Gefitinib in Treating Patients With Cervical Cancer

NCT00049556
View directory record Official record
Conditions
Cervical Cancer, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
gefitinib, immunohistochemistry staining method, surface-enhanced laser desorption/ionization-time of flight mass spectrometry, biopsy, sentinel lymph node biopsy
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 6, 2026, 9:50 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck

NCT00519077
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
Gefitinib
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
2
States / cities
Miami, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2016 · Synced Oct 6, 2026, 9:50 PM EDT
Completed Phase 2 Interventional

Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas

NCT00215995
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Cisplatin, Irinotecan, ZD 1839
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 13, 2012 · Synced Oct 6, 2026, 9:50 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer

NCT00238628
View directory record Official record
Conditions
Lung Cancer
Interventions
Bexarotene, Iressa
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 6, 2026, 9:50 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer

NCT00352105
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cisplatin, fluorouracil, Iressa, hyperfractionated radiation therapy
Drug · Radiation
Lead sponsor
David Adelstein
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 5, 2012 · Synced Oct 6, 2026, 9:50 PM EDT